TCGA-91-6828-01A-11R-1858-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.470
- INFLAMMATORY_RESPONSE+0.400
- PROTEIN_SECRETION+0.400
- ANDROGEN_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.370
- UV_RESPONSE_DN+0.370
- IL6_JAK_STAT3_SIGNALING+0.360
- ALLOGRAFT_REJECTION+0.350
- COMPLEMENT+0.330
- IL2_STAT5_SIGNALING+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- OXIDATIVE_PHOSPHORYLATION-0.370
- MYC_TARGETS_V1-0.330
- E2F_TARGETS-0.300
- KRAS_SIGNALING_DN-0.240
- DNA_REPAIR-0.190
- GLYCOLYSIS-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.160
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.150
- SPERMATOGENESIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.896 |
| 2 | TCGA-BA-5151-01A-01R-1436-07 | — | — | 0.853 |
| 3 | TCGA-69-7974-01A-11R-2187-07 | — | cohortA1 | 0.833 |
| 4 | SAMN03290930 | — | — | 0.833 |
| 5 | efe57fc7-7cf4-432b-86ff-9fd2d1a37b5e | — | — | 0.832 |
| 6 | MNG464 | — | — | 0.832 |
| 7 | TCGA-AR-A252-01A-11R-A169-07 | — | A | 0.830 |
| 8 | TCGA-A8-A0A1-01A-11R-A00Z-07 | — | A | 0.828 |
| 9 | BS_V0Q1G94N | low-grade glioma | — | 0.826 |
| 10 | SJEPD032296_D1.RNA-Seq | EPN | Anaplastic EPN | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |